An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
Latest Information Update: 25 Jul 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms CheckMate870
- Sponsors Bristol-Myers Squibb
- 24 Sep 2021 Status changed from active, no longer recruiting to completed.
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 22 Aug 2019 Planned End Date changed from 29 Jul 2022 to 29 Jul 2020.